News

Lighthouse Labs names new managing director

Lighthouse Labs has announced Art Espey as the new Managing Director, effective April 17. Art will replace outgoing Managing Director Paul Nolde, who will assume a similar role at Norfolk’s 757 Collab and 757 Angels organizations.

Art has long been involved with Lighthouse Labs, having previously served on the organization’s Board of Directors as Founding Vice Chair (2015 to 2018) and recently rejoining the Board. A serial entrepreneur, he has extensive experience in the full life cycle of startups, including scaling one of his ventures into a top 100 company in its industry with a staff of 500+, and gaining domestic and international leadership experience with an Inc. 500 company. His background includes work in healthcare, analytics, manufacturing, and construction, with significant experience in strategic leadership, private equity, diversity consulting, mergers and acquisitions, and business development. He holds degrees from the United States Merchant Marine Academy, Eastern Michigan University, and the University of Virginia. A former USMC Officer and Young Presidents’ Organization (YPO) member, Art has authored multiple books and taught a college-level course in change management. He currently sits on the Virginia Bio+Tech Partnership Authority Board of Directors and was formerly the Vice Chair of the American Red Cross in Southeastern Michigan. His wealth of experience will help Lighthouse Labs extend a record of success built on more than ten years of Investing in the lives of founders™. 

“After a decade, Lighthouse Labs is at an inflection point, with an opportunity to think big and reinvent our work with founders, investors, and the area’s innovation ecosystem,” Art shared. “I’m pleased to have the chance to build on the work previous leaders and the team have accomplished and look forward to continued success. I envision new and creative partnering opportunities with Paul and 757 Collab to foster innovation across the entire RVA757 megaregion.”

Nolde will continue with Lighthouse Labs through the end of the current cohort (May 30), and Art has already begun working with the team to ensure a smooth transition. Joe Kunkel, Lighthouse Labs Board Chair, stated “Lighthouse Labs has gained a stellar reputation and remained relevant by constantly refining our work to better support founders and their startups, and we are excited for the next chapter under Art’s leadership.”

 

Recent News

03/25/2026

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide. Grenova and its division partners are backed by

03/25/2026

Virginia Startups Raise Record $2.9 Billion in Venture Capital Investment in 2025 – Highest in Commonwealth History

Virginia Innovation Partnership Corp. (VIPC) today announced that the National Venture Capital Association (NVCA) reported Virginia attracted $2.9 billion in venture capital investment in 2025, marking an all-time high for the Commonwealth according to the 2025 Q4 Pitchbook-NVCA Venture Monitor Report.1 This record level of investment reflects the continued growth and momentum of Virginia’s startup

03/24/2026

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros uniquesingle-molecule-counting platform and reinforcing its potential to improve